A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. Investor Relations Contact: David Deuchler Gilmartin Group ir@certara.com Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its client ...

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A liv ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

RADNOR, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of gen ...

About Certara Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at www.certara.com. RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies ...

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the del ...

David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that todayÂ's conference is being recorded. I would now like to hand the conference over to your first speaker today, David Deuchler. In their remarks and responses to questions, management may mention some non-GAAP financial measures. Reconci ...

Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.09, delivering a surprise of -18.18%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Certara, which belongs to t ...

The net amount of deferred gains related to derivative instruments designated as cash flow hedges that is expected to be reclassified from accumulated other comprehensive gains into earnings over the next twelve months is $5,041. The Company's revenue consists of fees for perpetual and term licenses for its software products, post-contract customer support (referred to as maintenance), software as a service ("SaaS"), and professional services including training and other revenue. Revenue is recognized upon ...

Certara Reports First Quarter 2024 Financial Results Reiterates Full Year 2024 Financial Guidance First Quarter Highlights: • Services revenue was $57.3 million, flat compared to $57.3 million in the first quarter of 2023. • Adjusted EBITDA was $29.1 million, compared to $32.3 million in the first quarter of 2023. "We began 2024 with strong financial performance in software, driven by an impressive Net Retention Ratio of 114%, while our services business performed in line with our expectations. As we work t ...